Kura Oncology, Inc. (NASDAQ:KURA) management will conduct a conference call for 5th November 2020 at 8:00 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.kuraoncology.com
Earnings Expectation
Kura Oncology, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, KURA to report 3Q20 loss of $ 0.4 per share. For the full year, analysts anticipate loss of $ 1.65 per share bottom line.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The companys lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
